Kodiak Sciences Q1 net loss $43M, cash $245.9M; advances tarcocimab and KSI-101 trials

Kodiak Sciences Inc.

2024-Q1 EPS reported -$0.82

Net loss of $43.0M ($0.82 per share) vs $70.8M ($1.35) in Q1 2023; includes $18.4M stock-based compensation.
Cash and equivalents $245.9M; company expects runway into 2026.
R&D expenses $29.9M, down from $56.5M YoY due to reduced tarcocimab clinical activities.
GLOW2 Phase 3 diabetic retinopathy study actively enrolling; DAYBREAK wet AMD study activation targeted mid-2024.
Phase 1b APEX study of KSI-101 (anti-IL-6/VEGF-trap) in macular edema expected to start enrollment in June 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Kodiak Sciences Inc. reported the quarter ended March 31, 2024 results: net income $43.0 million, or $0.82 per share on both a basic and diluted basis, EPS $0.82 per share on both a basic and diluted basis.

Period: the quarter ended March 31, 2024
Net income: $43.0 million, or $0.82 per share on both a basic and diluted basis
EPS: $0.82 per share on both a basic and diluted basis
Result: reported results

Exact text from the filing

Kodiak Sciences Inc. (Nasdaq: KOD), today reported business highlights and financial results for the quarter ended March 31, 2024.

View on SEC.gov

1349 earnings releases filed in the last 30 days. Browse all earnings releases →

Kodiak Sciences Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-060455

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.